New Ocriplasmin Research Findings Presented at Upcoming ARVO 2016 Annual Meeting in Seattle

New data confirm appropriate patient selection leads to improved treatment outcomes, with no new safety signals observed

Leuven, Belgium, 27th April, 2016 – ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company, focused on developing innovative treatments for back of the eye diseases, announces that the Company will be presenting a number of scientific posters and presentations at the upcoming Association for Research in Vision and Ophthalmology (ARVO) 2016 Annual Meeting. The Meeting is being held from May 1st – 5th, 2016 in Seattle, US.

There will be 15 ocriplasmin-related communications delivered at ARVO. Data presented cover a wide range of presentations, abstracts and posters with preclinical research findings, real-world clinical data, and further characterization of results from different studies, including OASIS, ORBIT, and OVIID-I conducted in the US and Europe.

Ocriplasmin (JETREA®) is the first and only approved pharmacological treatment of symptomatic vitreomacular adhesion (VMA) / vitreomacular traction (VMT). The product is currently approved in 54 countries, including in the US.

Three years after its approval in the US and Europe, post-marketing reported data confirm the safety profile as described in the approved product label, without new safety signals. The reported adverse events are consistent with those observed in studies, and resolve in the majority of cases within time periods specified in the product label information. Moreover, new clinical studies and real-world data continue to confirm that appropriate patient selection leads to improved treatment outcomes.

Among other presentations, on Tuesday, 3rd May between 3.45pm – 5.30pm, ThromboGenics scientists or medical associates will be delivering poster presentations on the following topics:

- **Ocriplasmin in a porcine model for PVD induction**: to further characterize the activity profile of ocriplasmin at the vitreo-retinal interface.
- **Preclinical insights into ocriplasmin safety and mechanism of action**: to further confirm safety and mechanism of action of ocriplasmin in its interaction with vitreo-retinal tissues.
- **Evaluation of full-field electroretinogram (ERG) changes after ocriplasmin injection in a substudy of symptomatic vitreomacular adhesion subjects from the OASIS trial**: to evaluate the relationship of ERG changes with anatomic and visual outcomes for up to 24 months after a single injection of ocriplasmin 0.125 mg.
- **Repeated injections of ocriplasmin in the Göttingen mini-pig**: to determine safety of up to six consecutive injections of ocriplasmin at 4-week intervals.
Dr Patrik De Haes, CEO of ThromboGenics nv, comments, “The vast amount of ocriplasmin data presented at this year’s ARVO Annual meeting not only underscores our own commitment to continue to deliver high-quality research in support of the retina community, it is also a testimony of continued strong interest by esteemed members of that retina community. We are convinced that the research insights provided, combined with the overall growing body of clinical evidence, will further grow that interest and confidence when considering ocriplasmin as an increasingly attractive treatment option in a changed standard of care for the treatment of symptomatic VMA, this to the benefit of retina physicians and their patients suffering from this progressive and debilitating disease.”

- END –

For further information please contact:

<table>
<thead>
<tr>
<th>ThromboGenics</th>
<th>Citigate Dewe Rogerson</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wouter Piepers, Global Head of Corporate Communications &amp; IR</td>
<td>David Dible/Sylvie Berrebi</td>
</tr>
<tr>
<td>+32 16 75 13 10 / +32 478 33 56 32</td>
<td>Tel: +44 20 7282 9571</td>
</tr>
<tr>
<td><a href="mailto:wouter.piepers@thrombogenics.com">wouter.piepers@thrombogenics.com</a></td>
<td><a href="mailto:david.dible@citigatedr.co.uk">david.dible@citigatedr.co.uk</a></td>
</tr>
<tr>
<td></td>
<td><a href="mailto:sylvie.berrebi@citigatedr.co.uk">sylvie.berrebi@citigatedr.co.uk</a></td>
</tr>
</tbody>
</table>

About ThromboGenics

ThromboGenics is a biopharmaceutical company focused on developing innovative treatments for diabetic eye disease.

Thrombogenics’ attractive pipeline of disease modifying drug candidates is targeting the key segments of the diabetic eye disease market.

ThromboGenics is conducting the CIRCLE study, a Phase II clinical trial to assess THR-409 (ocriplasmin) as a potential treatment to prevent the patients with non-proliferative diabetic retinopathy to proliferative diabetic retinopathy.

THR-317, a PIGF inhibitor being developed to treat diabetic macular edema, or as a combination therapy with anti-VEGF treatments, is expected to enter the clinic in 2016.

In addition, THR-149, a plasma kallikrein inhibitor, which has resulted from research collaboration with Bicycle Therapeutics, and THR-687, an integrin antagonist, which was in-licensed from Galapagos are in late stage clinical development.

ThromboGenics pioneered the new drug category of pharmacological vitreolysis with JETREA® (ocriplasmin) which is now approved for the treatment of vitreomacular traction in 54 countries worldwide. ThromboGenics is commercializing JETREA® via its subsidiary ThromboGenics, Inc in the US. Alcon, a division of Novartis, commercializes JETREA® outside the United States.

ThromboGenics is headquartered in Leuven, Belgium, and is listed on the NYSE Euronext Brussels exchange under the symbol THR.

More information is available at [www.thrombogenics.com](http://www.thrombogenics.com)
Important information about forward-looking statements

Certain statements in this press release may be considered “forward-looking”. Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company’s Annual Report.

This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of ThromboGenics in any jurisdiction. No securities of ThromboGenics may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.